Brian Pruitt

651 total citations
20 papers, 481 citations indexed

About

Brian Pruitt is a scholar working on Oncology, Pediatrics, Perinatology and Child Health and Pathology and Forensic Medicine. According to data from OpenAlex, Brian Pruitt has authored 20 papers receiving a total of 481 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 5 papers in Pediatrics, Perinatology and Child Health and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Brian Pruitt's work include Childhood Cancer Survivors' Quality of Life (5 papers), Cancer Treatment and Pharmacology (5 papers) and Cancer survivorship and care (3 papers). Brian Pruitt is often cited by papers focused on Childhood Cancer Survivors' Quality of Life (5 papers), Cancer Treatment and Pharmacology (5 papers) and Cancer survivorship and care (3 papers). Brian Pruitt collaborates with scholars based in United States, Chile and South Africa. Brian Pruitt's co-authors include David P. Rose, Fang Fang, John W. Smith, Ellen Chuang, Elizabeth Tan-Chiu, Joyce O’Shaughnessy, Dale E. Shuster, Erdoğan Ertürk, George T. Bryan and Kumari Chandrawansa and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Brian Pruitt

19 papers receiving 452 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Brian Pruitt United States 10 319 80 74 73 65 20 481
T. Gulliford United Kingdom 8 230 0.7× 96 1.2× 56 0.8× 68 0.9× 134 2.1× 10 456
Rolf Kaaresen Norway 12 212 0.7× 165 2.1× 47 0.6× 62 0.8× 138 2.1× 23 450
SR Ebbs United Kingdom 6 219 0.7× 123 1.5× 73 1.0× 154 2.1× 140 2.2× 7 491
Kazuma Maeno Japan 10 214 0.7× 55 0.7× 51 0.7× 59 0.8× 144 2.2× 32 444
Daniel Mailo United States 9 449 1.4× 118 1.5× 51 0.7× 187 2.6× 226 3.5× 11 669
Jo Ann Davis United States 14 203 0.6× 35 0.4× 76 1.0× 80 1.1× 188 2.9× 30 852
Mariangela Bella Italy 7 180 0.6× 29 0.4× 28 0.4× 37 0.5× 116 1.8× 12 491
N. Afonso Portugal 13 244 0.8× 100 1.3× 86 1.2× 74 1.0× 106 1.6× 28 495
Anthony C. Evans United States 11 118 0.4× 66 0.8× 41 0.6× 145 2.0× 233 3.6× 14 517
Christina Yeon United States 8 258 0.8× 70 0.9× 97 1.3× 85 1.2× 76 1.2× 26 367

Countries citing papers authored by Brian Pruitt

Since Specialization
Citations

This map shows the geographic impact of Brian Pruitt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Pruitt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Pruitt more than expected).

Fields of papers citing papers by Brian Pruitt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Pruitt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Pruitt. The network helps show where Brian Pruitt may publish in the future.

Co-authorship network of co-authors of Brian Pruitt

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Pruitt. A scholar is included among the top collaborators of Brian Pruitt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Pruitt. Brian Pruitt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vahdat, Linda T., Brian Pruitt, Carol J. Fabian, et al.. (2009). Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane. Journal of Clinical Oncology. 27(18). 2954–2961. 201 indexed citations
2.
Blum, Joanne L., Brian Pruitt, Carol J. Fabian, et al.. (2007). Phase II study of eribulin mesylate (E7389) halichondrin b analog in patients with refractory breast cancer. Journal of Clinical Oncology. 25(18_suppl). 1034–1034. 7 indexed citations
3.
Pruitt, Brian, et al.. (2006). Detecting asymptomatic endometrial carcinoma by combined PET/CT. Community Oncology. 3(5). 246–255.
4.
5.
Rothenberg, Mace L., Jacqueline Benedetti, J. S. Macdonald, et al.. (2002). Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study. Annals of Oncology. 13(10). 1576–1582. 15 indexed citations
6.
Robinson, William R., et al.. (2002). Hospice utilization by male and female cancer patients in an end-of-life transition program.. PubMed. 57(2). 82–4. 3 indexed citations
7.
Pruitt, Brian. (2000). Early feeding after cesarean: a randomized clinical trial. Obstetrics and Gynecology. 95(6). S64–S64. 2 indexed citations
8.
Cummins, Martin J. & Brian Pruitt. (1999). Low-Dose Oral Use of Human Interferon-alpha in Cancer Patients. Journal of Interferon & Cytokine Research. 19(8). 937–941. 11 indexed citations
9.
10.
Case, Delvyn C., et al.. (1993). Phase II Study of Intravenous Idarubicin in Unfavorable Non-Hodgkin's Lymphoma. Leukemia & lymphoma. 10(sup1). 73–79. 9 indexed citations
11.
Pruitt, Brian, et al.. (1993). An educational intervention for newly‐diagnosed cancer patients undergoing radiotherapy. Psycho-Oncology. 2(1). 55–62. 31 indexed citations
12.
McMahon, Terry, et al.. (1992). Relationships Between Emotional Distress and Psychosocial Concerns Among Newly Diagnosed Cancer Patients. Journal of Psychosocial Oncology. 10(3). 57–74. 5 indexed citations
13.
Case, Delvyn C., et al.. (1992). Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma.. PubMed. 52(14). 3871–4. 9 indexed citations
14.
Pruitt, Brian, et al.. (1991). Prediction of Distress in the First Six Months After a Cancer Diagnosis. Journal of Psychosocial Oncology. 9(4). 91–102. 10 indexed citations
15.
Witte, Robert S., Brian Pruitt, Douglass C. Tormey, et al.. (1986). A phase I/II investigation of trioxifene mesylate in advanced breast cancer. Clinical and endocrinologic effects. Cancer. 57(1). 34–39. 19 indexed citations
16.
Pruitt, Brian, et al.. (1985). Program Development for Supportive Care of Cancer Patients. Journal of Psychosocial Oncology. 3(1). 95–100. 1 indexed citations
17.
Rose, David P. & Brian Pruitt. (1981). Plasma prolactin levels in patients with breast cancer. Cancer. 48(12). 2687–2691. 43 indexed citations
18.
Citrin, Dennis L., et al.. (1981). The use of serial bone scans in assessing response of bone metastases to systemic treatment. Cancer. 47(4). 680–685. 39 indexed citations
19.
Rose, David P., et al.. (1980). Influence of dosage schedule on the biological characteristics of N-nitrosomethylurea-induced rat mammary tumors.. PubMed. 40(2). 235–9. 57 indexed citations
20.
Rose, David P. & Brian Pruitt. (1979). Modification of the effect of a gonadoliberin analog on 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors by hormone replacement.. PubMed. 39(10). 3968–70. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by T. Gulliford Breakdown of academic impact, for papers by Rolf Kaaresen Breakdown of academic impact, for papers by SR Ebbs Breakdown of academic impact, for papers by Kazuma Maeno Breakdown of academic impact, for papers by Daniel Mailo Breakdown of academic impact, for papers by Jo Ann Davis Breakdown of academic impact, for papers by Mariangela Bella Breakdown of academic impact, for papers by N. Afonso Breakdown of academic impact, for papers by Anthony C. Evans Breakdown of academic impact, for papers by Christina Yeon
Rankless by CCL
2026